42
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Altered regulation of tau phosphorylation in a mouse model of down syndrome aging

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Down syndrome (DS) results from trisomy of human chromosome 21 (Hsa21) and is associated with an increased risk of Alzheimer's disease (AD). Here, using the unique transchromosomic Tc1 mouse model of DS we investigate the influence of trisomy of Hsa21 on the protein tau, which is hyperphosphorylated in Alzheimer's disease. We show that in old, but not young, Tc1 mice increased phosphorylation of tau occurs at a site suggested to be targeted by the Hsa21 encoded kinase, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A). We show that DYRK1A is upregulated in young and old Tc1 mice, but that young trisomic mice may be protected from accumulating aberrantly phosphorylated tau. We observe that the key tau kinase, glycogen synthase kinase3-β (GSK-3β) is aberrantly phosphorylated at an inhibitory site in the aged Tc1 brain which may reduce total glycogen synthase kinase3-β activity. It is possible that a similar mechanism may also occur in people with DS.

          Related collections

          Most cited references80

          • Record: found
          • Abstract: found
          • Article: not found

          Neuropathological stageing of Alzheimer-related changes

          Eighty-three brains obtained at autopsy from nondemented and demented individuals were examined for extracellular amyloid deposits and intraneuronal neurofibrillary changes. The distribution pattern and packing density of amyloid deposits turned out to be of limited significance for differentiation of neuropathological stages. Neurofibrillary changes occurred in the form of neuritic plaques, neurofibrillary tangles and neuropil threads. The distribution of neuritic plaques varied widely not only within architectonic units but also from one individual to another. Neurofibrillary tangles and neuropil threads, in contrast, exhibited a characteristic distribution pattern permitting the differentiation of six stages. The first two stages were characterized by an either mild or severe alteration of the transentorhinal layer Pre-alpha (transentorhinal stages I-II). The two forms of limbic stages (stages III-IV) were marked by a conspicuous affection of layer Pre-alpha in both transentorhinal region and proper entorhinal cortex. In addition, there was mild involvement of the first Ammon's horn sector. The hallmark of the two isocortical stages (stages V-VI) was the destruction of virtually all isocortical association areas. The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

            Glycogen synthase kinase-3 (GSK3) is implicated in the regulation of several physiological processes, including the control of glycogen and protein synthesis by insulin, modulation of the transcription factors AP-1 and CREB, the specification of cell fate in Drosophila and dorsoventral patterning in Xenopus embryos. GSK3 is inhibited by serine phosphorylation in response to insulin or growth factors and in vitro by either MAP kinase-activated protein (MAPKAP) kinase-1 (also known as p90rsk) or p70 ribosomal S6 kinase (p70S6k). Here we show, however, that agents which prevent the activation of both MAPKAP kinase-1 and p70S6k by insulin in vivo do not block the phosphorylation and inhibition of GSK3. Another insulin-stimulated protein kinase inactivates GSK3 under these conditions, and we demonstrate that it is the product of the proto-oncogene protein kinase B (PKB, also known as Akt/RAC). Like the inhibition of GSK3 (refs 10, 14), the activation of PKB is prevented by inhibitors of phosphatidylinositol (PI) 3-kinase.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

              Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes. Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase. We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its associated protein rictor are necessary for Ser473 phosphorylation and that a reduction in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector. The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1. Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.
                Bookmark

                Author and article information

                Journal
                Neurobiol Aging
                Neurobiol. Aging
                Neurobiology of Aging
                Elsevier
                0197-4580
                1558-1497
                April 2012
                April 2012
                : 33
                : 4-2
                : 828.e31-828.e44
                Affiliations
                [a ]University College London Institute of Neurology, London, UK
                [b ]MRC National Institute for Medical Research, London, UK
                Author notes
                [* ]Corresponding author at: University College London Institute of Neurology, Department of Neurodegenerative Disease, 3rd Floor Queen Square House, Queen Square, London WC1N 3BG, UK. Tel.: +44 207 676 2187; fax: +44 207 676 2180 f.wiseman@ 123456prion.ucl.ac.uk
                [1]

                Present address: Wolfson Institute for Biomedical Research and Department of Cell and Developmental Biology, University College London, London WC1E 6BT, UK.

                Article
                NBA7895
                10.1016/j.neurobiolaging.2011.06.025
                3314962
                21843906
                2ffd50e7-bb10-44ca-9e06-85937be1ff09
                © 2012 Elsevier Inc.

                This document may be redistributed and reused, subject to certain conditions.

                History
                : 13 October 2010
                : 5 April 2011
                : 23 June 2011
                Categories
                Abstract of Online Article

                Neurosciences
                down syndrome,dyrk1a,tau,gsk-3β,phosphorylation,alzheimer disease
                Neurosciences
                down syndrome, dyrk1a, tau, gsk-3β, phosphorylation, alzheimer disease

                Comments

                Comment on this article